Movement Alert｜RemeGen Rises 5.11% in Regular Trading, First A-Share Buyback Plan Boosts Market Confidence

Market Focus07-20

On July 20, RemeGen rose 5.11% in regular trading, trading at HK$81.3/share, with turnover of HK$83.15 million.

On the news front, the company's board of directors unanimously approved its first A-share buyback plan on July 19, with a total repurchase amount of RMB 25-50 million, a price cap of RMB 149/share, and a 12-month execution window. The repurchased shares will be used for employee stock ownership plans or equity incentives. The company stated the buyback aims to boost investor confidence and promote stable, sustainable development.

Additionally, the company's core product Telitacicept was recently included in the National Essential Drug List under the immunology category, further brightening its commercialization outlook. The broader innovative drug sector also rallied, with INNOVENT BIO up 4.16%, BEIGENE up 3.72%, and AKESO up 3.57%, reflecting continued capital inflows into the biotech sector.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181009720?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181009720","market":"hk","top_or_hot":-1,"title":"Movement Alert｜RemeGen Rises 5.11% in Regular Trading, First A-Share Buyback Plan Boosts Market Confidence","media":"Market Focus","content":"<p><p>On July 20, RemeGen rose 5.11% in regular trading, trading at HK$81.3/share, with turnover of HK$83.15 million.</p><p>On the news front, the company's board of directors unanimously approved its first A-share buyback plan on July 19, with a total repurchase amount of RMB 25-50 million, a price cap of RMB 149/share, and a 12-month execution window. The repurchased shares will be used for employee stock ownership plans or equity incentives. The company stated the buyback aims to boost investor confidence and promote stable, sustainable development.</p><p>Additionally, the company's core product Telitacicept was recently included in the National Essential Drug List under the immunology category, further brightening its commercialization outlook. The broader innovative drug sector also rallied, with INNOVENT BIO up 4.16%, BEIGENE up 3.72%, and AKESO up 3.57%, reflecting continued capital inflows into the biotech sector.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜RemeGen Rises 5.11% in Regular Trading, First A-Share Buyback Plan Boosts Market Confidence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜RemeGen Rises 5.11% in Regular Trading, First A-Share Buyback Plan Boosts Market Confidence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-20 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 20, RemeGen rose 5.11% in regular trading, trading at HK$81.3/share, with turnover of HK$83.15 million.</p><p>On the news front, the company's board of directors unanimously approved its first A-share buyback plan on July 19, with a total repurchase amount of RMB 25-50 million, a price cap of RMB 149/share, and a 12-month execution window. The repurchased shares will be used for employee stock ownership plans or equity incentives. The company stated the buyback aims to boost investor confidence and promote stable, sustainable development.</p><p>Additionally, the company's core product Telitacicept was recently included in the National Essential Drug List under the immunology category, further brightening its commercialization outlook. The broader innovative drug sector also rallied, with INNOVENT BIO up 4.16%, BEIGENE up 3.72%, and AKESO up 3.57%, reflecting continued capital inflows into the biotech sector.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1181009720","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181009720","pubTimestamp":1784512283,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 20, RemeGen rose 5.11% in regular trading, trading at HK$81.3/share, with turnover of HK$83.15 million.On the news front, the company's board of directors unanimously approved its first...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"走势提醒|RemeGen常规交易上涨5.11%，首个A股回购计划提振市场信心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On July 20, RemeGen rose 5.11% in regular trading, trading at HK$81.3/share, with turnover of HK$83.15 million.On the news front, the company's board of directors unanimously approved its first A-share buyback plan on July 19, with a total repurchase amount of RMB 25-50 million, a price cap of RMB 149/share, and a 12-month execution window. The repurchased shares will be used for employee stock ownership plans or equity incentives. The company stated the buyback aims to boost investor confidence and promote stable, sustainable development.Additionally, the company's core product Telitacicept was recently included in the National Essential Drug List under the immunology category, further brightening its commercialization outlook. The broader innovative drug sector also rallied, with INNOVENT BIO up 4.16%, BEIGENE up 3.72%, and AKESO up 3.57%, reflecting continued capital inflows into the biotech sector.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181009720","isCrawlerRequest":true}